Evidence map›Paper›PMID 28915558›Full record

ArticleOncotarget2017

Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.

Yoshihiro Ito, Peter K Vogt, Jonathan R Hart

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Cancer-AssociatedInternational journal of medical sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yoshihiro ItoDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, San Diego, CA, USA.
Peter K VogtDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, San Diego, CA, USA.
Jonathan R HartDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, San Diego, CA, USA.
Scripps Research Institute · US

Funding

Cancer genes: translating basics to applicationsR35CA197582 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI VOGT, PETER K · 2016 to 2022
$7.8M
Activation of silenced tumor suppressor genes by non-coding RNAR01CA151574 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI VOGT, PETER K · 2010 to 2014
$1.9M
The Antisense Transcriptome and the Epigenetics of Cancer.R01CA153124 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI VOGT, PETER K · 2010 to 2013
$1.2M
NCI NIH HHS R01 CA151574NCI NIH HHS R01 CA153124NCI NIH HHS R35 CA197582
6 · The paper itself

Abstract

Our understanding of isoform-specific activities of phosphatidylinositol 3-kinase (PI3K) is still rudimentary, and yet, deep knowledge of these non-redundant functions in the PI3K family is essential for effective and safe control of PI3K in disease. The two major isoforms of the regulatory subunits of PI3K are p85α and p85β, encoded by the genes PIK3R1 and PIK3R2, respectively. These isoforms show distinct functional differences that affect and control cellular PI3K activity and signaling [1-4]. In this study, we have further explored the differences between p85α and p85β by genetic truncations and substitutions. We have discovered unexpected activities of the mutant proteins that reflect regulatory functions of distinct p85 domains. These results can be summarized as follows: Deletion of the SH3 domain increases oncogenic and PI3K signaling activity. Deletion of the combined SH3-RhoGAP domains abolishes these activities. In p85β, deletion of the cSH2 domain reduces oncogenic and signaling activities. In p85α, such a deletion has an activating effect. The deletions of the combined cSH2 and iSH2 domains and also the deletion of the cSH2, iSH2 and nSH2 domains yield results that go in the same direction, generally activating in p85α and reducing activity in p85β. The contrasting functions of the cSH2 domains are verified by domain exchanges with the cSH2 domain of p85β exerting an activating effect and the cSH2 domain of p85α an inactivating effect, even in the heterologous isoform. In the cell systems studied, protein stability was not correlated with oncogenic and signaling activity. These observations significantly expand our knowledge of the isoform-specific activities of p85α and p85β and of the functional significance of specific domains for regulating the catalytic subunits of class IA PI3K.

Indexed as

domain exchangeiSH2 domainRhoGAP domainSH2 domainSH3 domain

Identifiers

PMID28915558
PMCPMC5593529
OpenAlexW2742294810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.